Article

Angioedema Resolves with Omalizumab

Author(s):

It appears that 300 mg of omalizumab (Xolair/Genentech) is effective in reducing angioedema, according to the results of a new study.

It appears that 300 mg of omalizumab (Xolair/Genentech) is effective in reducing angioedema, according to the results of a new study.

Appearing in the October 2016 edition of the Annals of Allergy, Asthma and Immunology, the study was written by James Zazzali, PhD, MPH, of Genentech Inc., South San Francisco, CA, and colleagues.

Approximately 40% of patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) experience the acute swelling of subcutaneous tissue, or angioedema.

Non-sedating histamine 1, (H1) has been the only approved treatment for CIU/CSU, but does not provide relief of symptoms for many patients. Omalizumab, when used as an add-on therapy to H1-antihistamines appears to be effective in Phase 3 studies.

The study ASTERIA I, compared patients in randomized groups who received either 75 mg of omalizumab, 150 mg of omalizumab, 300 mg of omalizumab, or placebo. ASTERIA II was similar with patients receiving either 75 mg of omalizumab, 150 mg of omalizumab, 300 mg of omalizumab, or placebo. GLACIAL included groups receiving 300 mg of omalizumab or placebo.

In all three studies, 44%-53% of patients were experiencing angioedema at baseline, and had similar disease activity. The researchers report, “During the active treatment period, use of 300 mg of omalizumab resulted in a reduction in the percentage of patients with angioedema and a reduction in overall angioedema days.”

The authors point out that in this study, patients and not physicians, reported both angioedema and angioedema management. Severity was not assessed, nor was rescue medication controlled-for in this study.

“Treatment with 300 mg of omalizumab was efficacious in reducing patient-reported angioedema in patients with CIU/SCU who were symptomatic despite a variety of treatments,” conclude the researchers.

Related Coverage:

Omalizumab Highly Effective for Treatment of Chronic Spontaneous Urticaria

Atopic Dermatitis Yields to Asthma Medication

Multiple Food Allergies Can Be Treated at the Same Time Using Asthma Drug

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Ashfaq Marghoob, MD: Artificial Intelligence, Smartphone Use for Pigmented Lesion Classification
Major Diagnostic Challenges for Pigmented Lesions, with Ashfaq Marghoob, MD
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
Atypical Clinical Presentations of Blistering Disease, with Donna Culton, MD, PhD
How to Address Blistering Diseases, with Donna Culton, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.